BioCatalystWatch
STTKWorkspace / STTK / OverviewCompany library
Price
Market cap
Next catalystExpected Q4 2026SL-325 — RECEPTIVE-HS1 · Trial initiationSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

SL-325

DR3 (TNFRSF25)

PreINDP1P2P3FilingApproved
Upcoming / outlook

SL-846

DR3 × IL-23R

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

SL-325

DR3 (TNFRSF25)

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

SL-325

DR3 (TNFRSF25)

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

SL-846

DR3 × IL-23R

PreINDP2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

SL-325

DR3 (TNFRSF25)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

PreINDP1P2P3FilingApproved
CD20 GADLEN

CD20

PreINDP1P2P3FilingApproved
SL-6159

PreINDP1P2P3FilingApproved
SL-279137

PreINDP1P2P3FilingApproved
SL-425

DR3 (TNFRSF25)

GADLEN™

CD20 × B7-H3

PreINDP1P2P3FilingApproved

History / paused

PVR × PVRL2 × PVRL3 × Nectin-4 × HVEM × LTβR

PreINDP1P2P3FilingApproved
SL-325

DR3 (TNFRSF25)

PreINDP1P2P3FilingApproved
SL-846

DR3 × IL-23R

Upcoming / outlook

PD-L1 × OX40

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

STTK PR & News

PR & News

STTK SEC archive